CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← Alto Neuroscience, Inc. (ANRO) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

Alto Neuroscience, Inc. (ANRO)

Pharmaceutical Preparations · market cap $1.1B · as of 2026-07-21

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-12-15 (est.)
Phase 2
Pipeline
13
programs
Upcoming events
3
next 90d+
Dossier
Ready
cached
Alto Neuroscience (ANRO) is a clinical-stage pharmaceutical company focused primarily on CNS disorders, with a pipeline spanning Major Depressive Disorder, Bipolar Depression, Treatment-Resistant Depression, and Schizophrenia. The company trades at ~$25.90 with a $909M market cap, ~$264M in cash (roughly 29 months of runway), and two near-term Phase 2 readouts — ALTO-100 in Bipolar Depression (est. August 15, 2026) and ALTO-300 in MDD (est. December 15, 2026) — acting as primary catalysts.
The catalyst path
  • 2026-12-15 (est.)Phase 2 · ALTO-300imp 7/10
  • 2027-09-15 (est.)Phase 2 · ALTO-100imp 7/10
  • 2027-11-15 (est.)Phase 2 · ALTO-207imp 7/10
Pipeline
AssetPhaseIndication
GB001 recombinant peptide spray low dose group、high dose groupPhase 2Healthy
ALTO-100Phase 2Bipolar Disorder I or II With a Major Depressive Episode
ALTO-300 oral (PO) tabletPhase 2Major Depressive Disorder
ALTO-100 PO tabletPhase 2Major Depressive Disorder
ALTO-300 PO TabletPhase 2Major Depressive Disorder
ALTO-300Phase 2Major Depressive Disorder
ALTO-101Phase 2Schizophrenia
PA1010Phase 2Chronic HBV Infection
PA9159 nasalPhase 2Allergic Rhinitis
ALTO-203Phase 2Major Depressive Disorder
PA9159 Metered-Dose InhalerPhase 2Bronchial Asthma
XKH004Phase 3Phase III
ALTO-207Phase 2Treatment-resistant Depression (TRD)
Price & technical context
3-month
-18.3%
6-month
+27.8%
12-month
+145.6%
52-wk range
$12.11–$36.64
vs 50-day MA
+6.3%
vs 200-day MA
+12.4%
Realized vol
73.7%
Max drawdown
-87.6%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for ANRO (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 13 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.